Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO 2020 Expert Video Report on sarcomas

Reporting from ESMO Virtual Congress 2020, Olivier Mir comments on potential therapeutic options in rare forms of Sarcomas.
He reports on the activity of regorafenib in metastatic relapsed Ewing Sarcoma, and shows interesting results from pembrolizumab in a cohort of patients with none of the potential biomarkers for this drug.


  • LBA68 - Results of the randomized, Placebo (PL)-controlled Phase II study evaluating the efficacy and safety of Regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma, on behalf of the French Sarcoma Group (FSG) and Unicancer
  • 1619O - High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcSé Pembrolizumab study

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.